Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration

W. H. Chang, D. J. Juang, S. K. Lin, J. D. Huang, Yui-wing F Lam, M. W. Jann, C. P. Chien

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A single dose of haloperidol decanoate 100 mg was administered to 15 schizophrenic patients. Blood samples were obtained prior to injection, 1 h, 3 h, 6 h, 8 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks and four weeks post-injection. Haloperidol and its reduced metabolite, reduced haloperidol, plasma levels were assayed by HPLC with electrochemical detection. The pharmacokinetic parameters of haloperidol were determined. The mean time of maximal (T(max)) plasma levels for haloperidol was 5.73 ± 0.80 days. The haloperidol plasma levels showed a biexponential decline with an elimination half-life of 15.78 ± 5.90 days. Reduced haloperidol was rapidly formed from the haloperidol. The T(max) of reduced haloperidol was 7.00 ± 2.35 days. The mean ratio reduced haloperidol/haloperidol was 0.155 ± 0.111. Since the T(max) occurs at approximately six days, a weekly loading dose of haloperidol decanoate is feasible during the transition from oral to depot therapy.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalHuman Psychopharmacology
Volume10
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Haloperidol
Injections
Half-Life
Pharmacokinetics
High Pressure Liquid Chromatography
haloperidol decanoate
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol

Keywords

  • haloperidol and reduced haloperidol plasma levels
  • haloperidol decanoate

ASJC Scopus subject areas

  • Pharmacology
  • Psychology(all)
  • Neuroscience(all)
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neurology
  • Clinical Neurology

Cite this

Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration. / Chang, W. H.; Juang, D. J.; Lin, S. K.; Huang, J. D.; Lam, Yui-wing F; Jann, M. W.; Chien, C. P.

In: Human Psychopharmacology, Vol. 10, No. 1, 1995, p. 47-51.

Research output: Contribution to journalArticle

Chang, W. H. ; Juang, D. J. ; Lin, S. K. ; Huang, J. D. ; Lam, Yui-wing F ; Jann, M. W. ; Chien, C. P. / Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration. In: Human Psychopharmacology. 1995 ; Vol. 10, No. 1. pp. 47-51.
@article{792ab57b80dd475fbec1936b17790b8f,
title = "Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration",
abstract = "A single dose of haloperidol decanoate 100 mg was administered to 15 schizophrenic patients. Blood samples were obtained prior to injection, 1 h, 3 h, 6 h, 8 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks and four weeks post-injection. Haloperidol and its reduced metabolite, reduced haloperidol, plasma levels were assayed by HPLC with electrochemical detection. The pharmacokinetic parameters of haloperidol were determined. The mean time of maximal (T(max)) plasma levels for haloperidol was 5.73 ± 0.80 days. The haloperidol plasma levels showed a biexponential decline with an elimination half-life of 15.78 ± 5.90 days. Reduced haloperidol was rapidly formed from the haloperidol. The T(max) of reduced haloperidol was 7.00 ± 2.35 days. The mean ratio reduced haloperidol/haloperidol was 0.155 ± 0.111. Since the T(max) occurs at approximately six days, a weekly loading dose of haloperidol decanoate is feasible during the transition from oral to depot therapy.",
keywords = "haloperidol and reduced haloperidol plasma levels, haloperidol decanoate",
author = "Chang, {W. H.} and Juang, {D. J.} and Lin, {S. K.} and Huang, {J. D.} and Lam, {Yui-wing F} and Jann, {M. W.} and Chien, {C. P.}",
year = "1995",
doi = "10.1002/hup.470100108",
language = "English (US)",
volume = "10",
pages = "47--51",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration

AU - Chang, W. H.

AU - Juang, D. J.

AU - Lin, S. K.

AU - Huang, J. D.

AU - Lam, Yui-wing F

AU - Jann, M. W.

AU - Chien, C. P.

PY - 1995

Y1 - 1995

N2 - A single dose of haloperidol decanoate 100 mg was administered to 15 schizophrenic patients. Blood samples were obtained prior to injection, 1 h, 3 h, 6 h, 8 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks and four weeks post-injection. Haloperidol and its reduced metabolite, reduced haloperidol, plasma levels were assayed by HPLC with electrochemical detection. The pharmacokinetic parameters of haloperidol were determined. The mean time of maximal (T(max)) plasma levels for haloperidol was 5.73 ± 0.80 days. The haloperidol plasma levels showed a biexponential decline with an elimination half-life of 15.78 ± 5.90 days. Reduced haloperidol was rapidly formed from the haloperidol. The T(max) of reduced haloperidol was 7.00 ± 2.35 days. The mean ratio reduced haloperidol/haloperidol was 0.155 ± 0.111. Since the T(max) occurs at approximately six days, a weekly loading dose of haloperidol decanoate is feasible during the transition from oral to depot therapy.

AB - A single dose of haloperidol decanoate 100 mg was administered to 15 schizophrenic patients. Blood samples were obtained prior to injection, 1 h, 3 h, 6 h, 8 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks and four weeks post-injection. Haloperidol and its reduced metabolite, reduced haloperidol, plasma levels were assayed by HPLC with electrochemical detection. The pharmacokinetic parameters of haloperidol were determined. The mean time of maximal (T(max)) plasma levels for haloperidol was 5.73 ± 0.80 days. The haloperidol plasma levels showed a biexponential decline with an elimination half-life of 15.78 ± 5.90 days. Reduced haloperidol was rapidly formed from the haloperidol. The T(max) of reduced haloperidol was 7.00 ± 2.35 days. The mean ratio reduced haloperidol/haloperidol was 0.155 ± 0.111. Since the T(max) occurs at approximately six days, a weekly loading dose of haloperidol decanoate is feasible during the transition from oral to depot therapy.

KW - haloperidol and reduced haloperidol plasma levels

KW - haloperidol decanoate

UR - http://www.scopus.com/inward/record.url?scp=0028947986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028947986&partnerID=8YFLogxK

U2 - 10.1002/hup.470100108

DO - 10.1002/hup.470100108

M3 - Article

AN - SCOPUS:0028947986

VL - 10

SP - 47

EP - 51

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

ER -